

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

BASE COAT MONO F15 MATT BASE MOUNICOT BLUE 22611

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1	Product	identifier
_		

Product name SDS code : BASE COAT MONO F15 MATT BASE MOUNICOT BLUE 22611 : 15722611B

1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses
Paint. Professional u	e Industrial use
	Uses advised against
All other uses	
Product use	: Solvent borne coating for exterior use.

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

1.4 Emergency telephone number

National advisory body/Poison Center		
471977		
34 01 34 01		
61 60 23 30		

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 Carc. 2, H351 STOT SE 3, H336 STOT RE 2, H373 Aquatic Chronic 3, H412



SECTION 2: Hazards identification

÷

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended. See Section 16 for the full text of the H statements declared above. See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



Signal word Hazard statements		Warning Flammable liquid and vapor. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. May cause drowsiness or dizziness. Suspected of causing cancer. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.
Precautionary statements		
Prevention	:	Obtain special instructions before use. Wear protective gloves, protective clothing and eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Do not breathe vapor. Wash hands thoroughly after handling.
Response	:	IF exposed or concerned: Get medical advice or attention. IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice or attention. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage	:	Store in a well-ventilated place. Keep container tightly closed. Keep cool.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	n-butyl acetate Reaction mass of ethylbenzene and xylene 4-methylpentan-2-one methyl methacrylate 4-morpholinecarbaldehyde Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate Hydroxyphenyl-benzotriazole derivatives Polymeric Benzotriazole
Supplemental label elements	:	Not applicable.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
Special packaging requirem	en	<u>ts</u>
Containers to be fitted with child-resistant fastenings	:	Not applicable.
-	:	Not applicable.
Date of issue/Date of revision		· 1_10_2022 Version : 1

Date of issue/Date of revision	: 1-10-2022	Version :1	5. S. S. S.
Date of previous issue	: No previous validation	2/22	AkzoNobel

SECTION 2: Hazards identification

2.3 Other hazards

Product meets the criteria : This mixture does not contain any substances that are assessed to be a PBT or a vPvB. for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : None known.

Other hazards which do not result in classification

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture Product/ingredient name Identifiers % Regulation (EC) No. Type				
U U			1272/2008 [CLP]	
n-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥25 - ≤50	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32 EC: 905-588-0	≥10 - ≤15	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
4-methylpentan-2-one	EC: 203-550-1 CAS: 108-10-1 Index: 606-004-00-4	≤3	Flam. Liq. 2, H225 Acute Tox. 4, H332 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336 EUH066	[1] [2]
aromatic hydrocarbons, C9	REACH #: 01-2119455851-35 EC: 918-668-5 CAS: 128601-23-0	≤2	Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 EUH066	[1]
Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119463258-33 EC: 919-857-5	≤3	Flam. Liq. 3, H226 STOT SE 3, H336 Asp. Tox. 1, H304 EUH066	[1]
methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	<1	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
4-morpholinecarbaldehyde	EC: 224-518-3 CAS: 4394-85-8	≤0.3	Skin Sens. 1, H317	[1]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6	≤0.3	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
Reaction mass of Bis (1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl	REACH #: 01-2119491304-40 EC: 915-687-0	≤0.3	Skin Sens. 1A, H317 Repr. 2, H361f Aquatic Acute 1, H400	[1]
Date of issue/Date of revision	: 1-10-2022	Version		
Date of previous issue	: No previous validation	3/22	Akzo	Nobe

SECTION 3: Compositio	n/information on i	ngredients		
1,2,2,6,6-pentamethyl-4-piperidyl sebacate	CAS: 1065336-91-5		(M=1) Aquatic Chronic 1, H410 (M=1)	
Hydroxyphenyl-benzotriazole derivatives	REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2	≤0.3	Skin Sens. 1, H317 Aquatic Chronic 2, H411	[1]
cyclohexanone	REACH #: 01-2119453616-35 EC: 203-631-1 CAS: 108-94-1 Index: 606-010-00-7	≤0.3	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119456620-43 EC: 926-141-6	≤0.3	Asp. Tox. 1, H304 EUH066	[1]
Polymeric Benzotriazole	CAS: 104810-47-1	≤0.3	Skin Sens. 1, H317 Aquatic Chronic 2, H411	[1]
cumene	REACH #: 01-2119473983-24 EC: 202-704-5 CAS: 98-82-8 Index: 601-024-00-X	≤0.1	Flam. Liq. 3, H226 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 2, H411	[1] [2]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: Immediately flush eyes with p eyelids. Check for and remov minutes. Get medical attention	e any contact lenses. Contin	
Inhalation	: Remove victim to fresh air an If it is suspected that fumes a mask or self-contained breath or if respiratory arrest occurs, personnel. It may be dangero resuscitation. Get medical at If unconscious, place in recov Maintain an open airway. Loo waistband.	re still present, the rescuer sh ing apparatus. If not breathin provide artificial respiration of ous to the person providing aid tention. If necessary, call a po rery position and get medical a	ould wear an appropriate ng, if breathing is irregular r oxygen by trained d to give mouth-to-mouth bison center or physician. attention immediately.
Skin contact	: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.		
Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	4/22	AkzoNobel

SECTION 4: First aid measures

Ingestion	: Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such
Protection of first-aiders	 as a collar, tie, belt or waistband. No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate
	mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate, 4-morpholinecarbaldehyde, Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate, Hydroxyphenyl-benzotriazole derivatives, Polymeric Benzotriazole. May produce an allergic reaction.

Over-exposure signs/symptoms

Eye contact	Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
o	

SECTION 5: Firefighting measures

5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising f	rom the substance or mixture
Hazards from the substance or mixture	: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	te	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.
6.3 Methods and materials for	r c	ontainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal

contractor.



SECTION 6: Accidental release measures

Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
6.4 Reference to other sections	 See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapor or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

Category	Notification and MAPP threshold	Safety report threshold
P5c	5000 tonne	50000 tonne

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific	: Not available.
solutions	



Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 BASE COAT MONO F15 MATT BASE MOUNICOT BLUE 22611

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits			
n-butyl acetate	(Finland, 12/2 STEL: 960 m STEL: 200 p	ng/m [°] 15 minutes. pm 15 minutes. g/m³ 8 hours.	try of Social Affairs
Reaction mass of ethylbenzene a	(Finland, 12/2 STEL: 440 m STEL: 100 p	ccupational Health, Minis 2019). Absorbed through s ng/m ³ 15 minutes. pm 15 minutes. g/m ³ 8 hours. n 8 hours.	-
4-methylpentan-2-one	(Finland, 12/2 STEL: 210 m	ng/m [°] 15 minutes. m 15 minutes. /m³ 8 hours.	try of Social Affairs
methyl methacrylate	Institute of O (Finland, 12/2 STEL: 210 m	ccupational Health, Minis 2019). ng/m³ 15 minutes. m 15 minutes. /m³ 8 hours.	try of Social Affairs
2-methoxy-1-methylethyl acetate	Institute of O (Finland, 6/20 TWA: 50 ppr TWA: 270 m STEL: 100 p	ccupational Health, Minis 018). Absorbed through sl	-
cyclohexanone	(Finland, 12/2 STEL: 82 mg		
cumene	(Finland, 12/2 STEL: 250 m STEL: 50 pp	ccupational Health, Minis 2019). Absorbed through s ng/m ³ 15 minutes. m 15 minutes. g/m ³ 8 hours. n 8 hours.	
procedures	If this product contains ingredi atmosphere or biological moni of the ventilation or other contr protective equipment. Referen the following: European Stand the assessment of exposure b limit values and measurement atmospheres - Guide for the a of exposure to chemical and b (Workplace atmospheres - Ge for the measurement of chemi	toring may be required to de rol measures and/or the nec nece should be made to mon lard EN 689 (Workplace atr y inhalation to chemical age strategy) European Standa pplication and use of procee iological agents) European neral requirements for the p	etermine the effectiveness cessity to use respiratory itoring standards, such as nospheres - Guidance for ents for comparison with ard EN 14042 (Workplace dures for the assessment Standard EN 482 performance of procedures
Date of issue/Date of revision	: 1-10-2022	Version :1	
Date of previous issue	: No previous validation	8/22	AkzoNobel

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 BASE COAT MONO F15 MATT BASE MOUNICOT BLUE 22611

SECTION 8: Exposure controls/personal protection

documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Туре	Exposure	Value	Population	Effects
n-butyl acetate	DNEL	Long term Oral	3.4 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	3.4 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	7 mg/kg	Workers	Systemic
			bw/day		
	DNEL	Long term	12 mg/m ³	General	Systemic
		Inhalation	U U	population	
	DNEL	Long term	48 mg/m ³	Workers	Systemic
		Inhalation			-,
	DNEL	Long term	102.34 mg/	General	Local
	DITEE	Inhalation	m ³	population	Loodi
	DNEL	Long term	480 mg/m ³	Workers	Local
	DILLE	Inhalation	400 mg/m	Wonters	Loodi
	DNEL	Short term	850.7 mg/	General	Local
	DINEL	Inhalation	859.7 mg/ m³		LUCAI
				population	Sustamia
	DNEL	Short term	859.7 mg/	General	Systemic
		Inhalation	m^3	population	
	DNEL	Short term	960 mg/m ³	Workers	Local
		Inhalation			
	DNEL	Short term	960 mg/m ³	Workers	Systemic
		Inhalation			
Reaction mass of ethylbenzene an	d DNEL	Long term Oral	1.6 mg/kg	General	Systemic
xylene			bw/day	population	
	DNEL	Long term	14.8 mg/m ³	General	Systemic
		Inhalation	_	population	
	DNEL	Long term	77 mg/m³	Workers	Systemic
		Inhalation	l J		-
	DNEL	Long term Dermal	108 mg/kg	General	Systemic
			bw/day	population	,
	DNEL	Long term Dermal	180 mg/kg	Workers	Systemic
			bw/day		-,
	DNEL	Short term	289 mg/m ³	Workers	Local
		Inhalation	200 mg/m		
	DNEL	Short term	289 mg/m ³	Workers	Systemic
		Inhalation	200 mg/m	WOINERS	Cysternic
4-methylpentan-2-one	DNEL		12 malka	General	Systemia
4-methylpentan-2-0ne	DNEL	Long term Oral	4.2 mg/kg	General	Systemic
		Long torms Domest	bw/day	population	Quatara:-
	DNEL	Long term Dermal	4.2 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	11.8 mg/	Workers	Systemic
			kg bw/day		l
	DNEL	Long term	14.7 mg/m ³		Local
		Inhalation		population	
	DNEL	Long term	14.7 mg/m ³	General	Systemic
		Inhalation		population	
	DNEL	Long term	83 mg/m³	Workers	Local
		Inhalation	_		
	DNEL	Long term	83 mg/m³	Workers	Systemic
		Inhalation			-
	DNEL	Short term	155.2 mg/	General	Local
		Inhalation	m ³	population	
	DNEL	Short term	155.2 mg/	General	Systemic
		Inhalation	m ³	population	e jeternio
	DNEL	Short term	208 mg/m ³	Workers	Local
		Inhalation	200 mg/m	WOINERS	LUUAI
	DNEL	Short term	208 mg/m^3	Workers	Svetomia
			208 mg/m ³		Systemic
e of issue/Date of revision :1	10-2022		Version	:1	
					AkzoNo



SECTION 8: Exposure controls/personal protection

		Inhalation	0.0	Canaral	Quatara:-
methyl methacrylate	DNEL	Long term Dermal	8.2 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	13.67 mg/ kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	74.3 mg/m ³	General population	Systemic
	DNEL	Long term	104 mg/m ³	General	Local
	DNEL	Inhalation Long term	208 mg/m³	population Workers	Local
	DNEL	Inhalation Long term	208 mg/m³	Workers	Systemic
4-morpholinecarbaldehyde	DNEL	Inhalation Long term Oral	8 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	8 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	14 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	29 mg/m ³	General population	Systemic
	DNEL	Long term Inhalation	98 mg/m³	Workers	Systemic
cyclohexanone	DNEL	Short term Dermal	1 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	1 mg/kg bw/day	General population	Systemic
	DNEL	Short term Oral	1.5 mg/kg bw/day	General population	Systemic
	DNEL	Long term Oral	1.5 mg/kg bw/day	General population	Systemic
	DNEL	Short term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Dermal	4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	10 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	20 mg/m ³	General population	Local
	DNEL	Short term Inhalation	20 mg/m³	General population	Systemic
	DNEL	Short term Inhalation	40 mg/m ³	General population	Local
	DNEL	Long term Inhalation	40 mg/m³	Workers	Local
	DNEL	Long term Inhalation	40 mg/m ³	Workers	Systemic
	DNEL	Short term Inhalation	80 mg/m ³	Workers	Local
	DNEL	Short term Inhalation	80 mg/m ³	Workers	Systemic
cumene	DNEL	Long term Dermal	1.2 mg/kg bw/day	General population	Systemic
	DNEL	Long term Oral	5 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	15.4 mg/ kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	16.6 mg/m ³	General population Workers	Systemic
	DNEL	Long term Inhalation Short term	100 mg/m ³	Workers Workers	Systemic Local
a of ionuo/Data of revision			250 mg/m ³		LUCAI
e of issue/Date of revision	: 1-10-2022		Version	:1	AkzoNob

Conforms to Regulation (EC) N			•	ACH), Annex II, as a IO F15 MATT BASE MOU	•	•	ation (EU) 2020/878
SECTION 8: Exposu	re c	ontrol	s/p	ersonal prote	ction		
-			-	Inhalation			
PNECs		ľ					
No PNECs available.							
8.2 Exposure controls							
Appropriate engineering controls		ventilation contamina controls a	n or ants Ilso	adequate ventilation other engineering co below any recommended need to keep gas, va its. Use explosion-pr	ntrols to kee ended or stat apor or dust o	p worker exposure utory limits. The e concentrations bel	e to airborne engineering
Individual protection meas	ures						
Hygiene measures		pefore ea Appropria Contamin contamin	ting ite t ate ateo	forearms and face to smoking and using echniques should be d work clothing should clothing before reus close to the workstat	the lavatory a used to remain d not be allowing. Ensure	and at the end of t ove potentially cor wed out of the wor	he working period. ntaminated clothing. kplace. Wash
Eye/face protection		assessme gases or	ent dus	ear complying with an indicates this is nece ts. If contact is possi sessment indicates a	ssary to avoi ble, the follo	d exposure to liqui wing protection sh	id splashes, mists, ould be worn,
Skin protection							
Hand protection		be worn a this is neo check dui should be different f	it al cess ing no or c ubst	istant, impervious gla I times when handling sary. Considering the use that the gloves a ted that the time to b lifferent glove manufa ances, the protection	g chemical pi e parameters are still retain reakthrough acturers. In t	roducts if a risk as specified by the g ing their protective for any glove mate he case of mixture	sessment indicates love manufacturer, e properties. It erial may be es, consisting of
		protection recomme When on (breakthro Recommo	nde nde y bi oug end	ged or frequently rep less of 6 (breakthroug ed. Recommended g rief contact is expecte h time >30 minutes a ed gloves: Nitrile, thic d be replaced regula	h time >480 i loves: Viton (ed, a glove w ccording to E ckness ≥ 0.12	minutes according ® or Nitrile, thickno ith protection class EN374) is recomm 2 mm.	i to EN374) is ess ≥ 0.38 mm. s of 2 or higher ended.
				ance or effectiveness nage and poor maint		may be reduced b	oy physical/
		product is	the	st check that the final e most appropriate ar ded in the user's risk	nd takes into	account the partic	
Body protection	,	being per before ha wear anti- discharge Europear	forn ndli sta s, c Sta	tective equipment for ned and the risks inve ng this product. Whe tic protective clothing clothing should includ andard EN 1149 for fi	olved and sh en there is a . For the gre e anti-static o	ould be approved risk of ignition fror eatest protection fr overalls, boots and	by a specialist n static electricity, rom static d gloves. Refer to

requirements and test methods. : Appropriate footwear and any additional skin protection measures should be Other skin protection selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.



SECTION 8: Exposure controls/personal protection

Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties 9.1 Information on basic physical and chemical properties

9.1 Information on basic physical	a	nd chemical properties
<u>Appearance</u>		
Physical state	:	Liquid.
Color	:	Blue.
Odor	:	Characteristic.
Odor threshold	:	Not available.
рН	:	Not available.
Melting point/freezing point	:	Not available.
Initial boiling point and boiling range	:	Not available.
Flash point	:	Closed cup: 27°C
Evaporation rate	:	Not available.
Flammability (solid, gas)	:	Not available.
Upper/lower flammability or explosive limits	:	Not available.
Vapor pressure	:	Not available.
Vapor density	:	Highest known value: 4 (Air = 1) (n-butyl acetate). Weighted average: 3.92 (Air = 1)
Density	:	0.99 g/cm ³
Solubility(ies)	:	Insoluble in the following materials: cold water.
Partition coefficient: n-octanol/ water	:	Not available.
Auto-ignition temperature	:	Not available.
Decomposition temperature	:	Not available.
Viscosity	:	Kinematic (room temperature): 10.1 cm²/s Kinematic (40°C): 1.01 cm²/s

SECTION 10: Stability and reactivity						
10.1 Reactivity	No specific test data related to reactivity available for this product or its ingredients.					
10.2 Chemical stability	The product is stable.					
10.3 Possibility of hazardous reactions	Under normal conditions of storage and use, hazardous reactions will not occur.					
10.4 Conditions to avoid	Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.					
10.5 Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials					
Date of issue/Date of revision	:1-10-2022 Version :1					
Date of previous issue	: No previous validation 12/22 AkzoNobel					

SECTION 10: Stability and reactivity

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

n-butyl acetate LC50 Inhalation Gas. LC50 Inhalation Vapor Rat 390 ppm 4 hours n-butyl acetate LC50 Inhalation Vapor Mouse 6 g/m² 2 hours LD50 Dermal Rabbit 17600 mg/kg - - LD50 Oral Guinea pig Mouse 6 g/kg - - LD50 Oral Rabbit 230 mg/kg - - - LD50 Oral Rat 10768 mg/kg - - - LD50 Oral Rat 10768 mg/kg - - - LD50 Intraperitoneal Mouse 280 mg/kg - - LD50 Intraperitoneal Guinea pig 1000 mg/kg - - LD50 Intraperitoneal Mouse 1850 mg/kg - - LD50 Oral Mouse 1850 mg/kg - - - LD50 Oral Mouse 1850 mg/kg - - - LD50 Oral Rat 2800 mg/kg - - - - <t< th=""><th>Product/ingredient name</th><th>Result</th><th>Species</th><th>Dose</th><th>Exposure</th></t<>	Product/ingredient name	Result	Species	Dose	Exposure
LCS0Inhiation VaporMouse6 g/m³2 hoursLDS0DemailRabbit>17600 mg/kg-LDS0OralGuinea pig4700 mg/kg-LDS0OralMouse6 g/kg-LDS0OralRabbit3200 mg/kg-LDS0DralRat10768 mg/kg-LDS0IntaperitonealGuinea pig800 mg/kg-4-methylpentan-2-oneLDS0IntaperitonealGuinea pig800 mg/kg-LDS0IntaperitonealGuinea pig1600 mg/kg-LDS0IntaperitonealMouse2850 mg/kg-LDS0IntaperitonealMouse1600 mg/kg-LDS0IntaperitonealMouse1800 mg/kg-LDS0IntaperitonealMouse1800 mg/kg-LDS0IntaperitonealRat2080 mg/kg-LDS0OralRat2800 mg/kg-LDS0IntaperitonealRabbit5 g/kg-LDS0IntaperitonealRabbit1328 mg/kg-LDS0IntaperitonealGuinea pig5954 mg/kg-LDS0IntaperitonealRabbit8700 mg/kg-LDS0IntaperitonealRabbit1328 mg/kg-LDS0IntaperitonealRat1328 mg/kg-LDS0IntaperitonealRabbit8700 mg/kg-LDS0IntaperitonealRat708 mg/kg-LDS0Intap	butyl acetate	LC50 Inhalation Gas.	Rat	390 ppm	4 hours
LDS0 DermalRabbit> 17600 mg/kg-LDS0 IntraperitonealGuinea pig4700 mg/kg-LDS0 OralGuinea pig200 mg/kg-LDS0 OralRabbit3200 mg/kg-LDS0 OralRabit2200 mg/kg-LDS0 OralRabit3200 mg/kg-ethylbenzene and xyleneLCS0 IntraperitonealMouse268 mg/kg-4-methylpentan-2-oneLDS0 IntraperitonealMouse268 mg/kg-LDS0 IntraperitonealMouse1600 mg/kgLDS0 IntraperitonealMouse1900 mg/kgLDS0 OralGuinea pig1600 mg/kgLDS0 OralMouse1900 mg/kgLDS0 OralMouse1800 mg/mgLDS0 OralMouse1800 mg/mgLDS0 OralRat7800 mg/kgLDS0 IntraperitonealRabbit> 5 g/kg-LDS0 IntraperitonealRabbit25 g/kg-LDS0 IntraperitonealRat1326 mg/kg-LDS0 OralRat7720 mg/kg-LDS0 OralRat77800 mg/kg-LDS0 IntraperitonealRabbit594 mg/kg-LDS0 OralRat7780 mg/kg-LDS0 OralRat7782 mg/kg-LDS0 OralRat7780 mg/kg-LDS0 OralRat778 mg/kg-LDS0 OralRat778 mg/kg-<		LC50 Inhalation Vapor	Mouse		2 hours
LD50 Intraperitoneal LD50 Mouse Guinea pig H0000 1230 mg/kg mg/kg - Reaction mass of ethylbenzene and xylene 4-methylpentan-2-one LD50 Oral Rabit 3200 mg/kg - LD50 Oral Rat 10768 mg/kg - - 4-methylpentan-2-one LD50 Intraperitoneal LD50 Mouse 286 mg/kg - LD50 Intraperitoneal to50 Mouse 286 mg/kg - - LD50 Intraperitoneal LD50 Mouse 1900 mg/kg - - LD50 Intraperitoneal LD50 Mouse 2850 mg/kg - - LD50 Oral Mouse 1900 mg/kg - - LD50 Oral Rat 2000 mg/kg - - LD50 Oral Rat 2000 mg/kg - - - LD50 Oral Rat 78000 mg/kg - - - methyl methacrylate LC50 Inhalation Vapor Mouse 1350 <td></td> <td></td> <td></td> <td></td> <td>-</td>					-
Lb50 OralGuinea pig Mouse4700 mg/kg G G/g-Reaction mass of ethylbenzene and xylene 4-methylpentan-2-oneLD50 OralRat10768 mg/kg 1050 IntraperitonealRat10768 mg/kg 1050 pm-LD50 IntraperitonealGuinea pig LD50 IntraperitonealGuinea pig Rat800 mg/kg 200 ppm-LD50 IntraperitonealGuinea pig LD50 Oral800 mg/kg G-LD50 IntraperitonealRat400 mg/kg 4-LD50 OralGuinea pig LD50 Oral1600 mg/kg G-LD50 OralMouse286 mg/kg 4-LD50 OralMouse1800 mg/kg 4-LD50 OralRat2080 mg/kg 4-LD50 OralRat2080 mg/kg 4-LD50 OralRat7800 mg/m3 44 hoursLD50 OralRat18500 mg/kg 4-LD50 IntraperitonealMouse945 mg/kg 4-LD50 IntraperitonealMouse3825 mg/kg 4-LD50 IntraperitonealMouse3825 mg/kg 4-LD50 IntraperitonealMouse3825 mg/kg 4-LD50 IntraperitonealMouse3825 mg/kg 4-LD50 OralRatbit770 mg/kg 4-LD50 IntraperitonealRat780 mg/kg 4-LD50 IntraperitonealMouse3825 mg/kg 4-LD50 IntraperitonealRat700 mg/kg 4-LD50 IntraperitonealRat1300 mg/kg 4<					_
Reaction mass of ethylbenzene and xylene 4-methylpentan-2-oneLD50 Oral LD50 OralMouse Rat6 g/kg 3200 mg/kg 3200 ppm4 hours4-methylpentan-2-oneLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig LD50 Intraperitoneal800 mg/kg Rat-LD50 Intraperitoneal LD50 IntraperitonealMouse Guinea pig LD50 Oral800 mg/kg Rat-LD50 Intraperitoneal LD50 OralMouse Guinea pig LD50 Oral1800 mg/kg Mouse-LD50 Intraperitoneal LD50 OralMouse Mouse1800 mg/kg P-LD50 Oral LD50 Oral LD50 OralRat Rat2080 mg/kg P-LD50 Oral LD50 Oral LD50 OralRat Rat2080 mg/kg P-Meuse LD50 Oral LD50 Oral LD50 Oral LD50 OralRat Rat2080 mg/kg P-LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 OralGuinea pig Rat Rat Rat1800 mg/kg P-4-morpholinecarbaldehyde cyclohexanoneLD50 Oral LD50 OralMouse Rat Rat Rat Rat7872 mg/kg P-4-morpholinecarbaldehyde cyclohexanoneLD50 Intraperitoneal LD50 Intraperitoneal LD50 IntraperitonealRat <br< td=""><td></td><td></td><td></td><td>4700 mg/kg</td><td>_</td></br<>				4700 mg/kg	_
Reaction mass of ethylbenzene and xylene 4-methylpentan-2-oneLD50 Oral LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal Guinea pig LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral Rat <br< td=""><td></td><td></td><td></td><td></td><td>_</td></br<>					_
Reaction mass of ethylbenzene and xylene 4-methylpentan-2-oneLD50 Intraperitoneal LD50 IntraperitonealRat10768 mg/kg S000 ppm-4-methylpentan-2-oneLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Rat800 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat400 mg/kg-LD50 Intraperitoneal LD50 OralRat2850 mg/kg-LD50 Oral LD50 OralMouse2850 mg/kg-LD50 Oral LD50 OralRat2800 mg/kg-LD50 Oral LD50 OralRat2800 mg/kg-LD50 Oral LD50 OralRat2800 mg/kg-LD50 Oral LD50 OralRat78000 mg/m³2 hoursLC50 Inhalation Vapor LD50 IntraperitonealRat1328 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig S954 mg/kgLD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 OralRat7088 mg/kg-LD50 Oral LD50 OralRat7088 mg/kg-LD50 Oral LD50 OralRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse5954 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1300 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1300 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1300 mg/kg- <t< td=""><td></td><td></td><td></td><td></td><td>-</td></t<>					-
Reaction mass of ethylbenzene and xylene 4-methylpentan-2-one LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral Rat T828 mg/kg - LD50 Oral LD50 Oral Rat T828 mg/kg - LD50 Intraperitoneal Rat T300 mg/kg - LD50 Oral Rat T300 mg/kg - LD50 Oral Rat T300 mg/kg - LD50 Oral Rat T300 mg/kg - LD50 Oral Rat T300 mg/kg - LD50 Oral Rat T300 mg/kg - LD50 Oral Rat T300 mg/kg - C50 Inhalation Vapor Mouse T3000 mg/m ³ Thours LC50 Inhalation Vapor Mouse T000 mg/kg - C50 Inhalation Vapor Nouse T3000 mg/kg - C50 Inhalation Vapor Nouse T3000 mg/kg - C50 Inhalation Vapor Nouse T3000 mg/kg - C50 Inhalation Vapor Nouse T500 mg/kg - C50 mg/kg - C50 Inhalation Vapor					-
ethylbenzene and xyleneLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Mouse800 mg/kg 268 mg/kg-4-methylpentan-2-oneLD50 Intraperitoneal LD50 IntraperitonealRat400 mg/kg-LD50 Intraperitoneal LD50 OralRat400 mg/kg-LD50 OralMouse1900 mg/kg-LD50 OralMouse2868 mg/kg-LD50 OralRat2080 mg/kg-LD50 OralRat4600 mg/kg-LD50 OralRat78000 mg/m34 hoursLD50 IntraperitonealMouse18500 mg/m34 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealGuinea pig198 mg/kg-LD50 IntraperitonealMouse3625 mg/kg-LD50 IntraperitonealMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7088 mg/kg-LD50 OralRat6000 ppm4 hoursLD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 OralRat6500 uL/kg-LD50 IntraperitonealRabbit1 mL/kg-LD50 SubcutaneousRat6000 ppm4 hoursLD50 IntraperitonealRabbit1 mL/kg-LD50 IntraperitonealRabbit1 mL/kg-LD50 IntraperitonealRabbit1 mL/kg-LD50 IntraperitonealRabbit					-
4-methylpentan-2-one LD50 Intraperitoneal Guinea pig 800 mg/kg - LD50 Intraperitoneal Mouse 268 mg/kg - LD50 Oral Guinea pig 1600 mg/kg - LD50 Oral Guinea pig 1600 mg/kg - LD50 Oral Mouse 2850 mg/kg - LD50 Oral Rat 2080 mg/kg - LD50 Oral Rat 4600 mg/kg - LD50 Oral Rat 4600 mg/kg - LD50 Oral Rat 4600 mg/kg - LD50 Oral Rat 78000 mg/m ³ 2 hours LD50 Dermal Ratb 75 g/kg - LD50 Intraperitoneal Mouse 945 mg/kg - LD50 Oral Rat 1328 mg/kg - LD50 Intraperitoneal Mouse 945 mg/kg - LD50 Oral Mouse 945 mg/kg - LD50 Oral Mouse 945 mg/kg - LD50 Oral Mouse 95954 mg/kg - LD50 Oral Ratb 7600 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Rat 7008 mg/kg - LD50 Subcutaneous Rat 7008 mg/kg - LD50 Subcutaneous Rat 7008 mg/kg - LD50 Intraperitoneal Mouse 1300 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Oral Rat 1620 UL/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Oral Rat 1620 UL/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Oral Rat 1620 UL/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Intraperitoneal Rat 11300 mg/kg - LD50 Intraperitoneal Rat 11300 mg/kg - LD50 Intraperitoneal Rat 11300 mg/kg - LD50 Intraperitoneal Rat 11200 mg/kg - LD50 Intraperitoneal Rat 11200 mg/kg - LD50 Inhalati		LC50 Innalation Gas.	Rai	5000 ppm	4 nours
4-morpholinecarbaldehyde cyclohexanone 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde 4-morpholinecarbaldehyde				000	
LD50 Intraperitoneal LD50 OralRat400 mg/kg Guinea pig-LD50 OralGuinea pig1600 mg/kg-LD50 OralMouse2850 mg/kg-LD50 OralRat2808 mg/kg-LD50 OralRat4600 mg/kg-LD50 OralRat4600 mg/kg-LD50 OralRat78000 mg/m32 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 IntraperitonealGuinea pig5954 mg/kg-LD50 IntraperitonealRat8700 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralRat8700 mg/kg-LD50 OralRat8700 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 SubcutaneousRat6500 ul/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50					-
 LD50 Oral LD50 Oral Mouse HOD mg/kg LD50 Oral Mouse HOD mg/kg LD50 Oral Mouse Rat 2080 mg/kg LD50 Oral Rat 78000 mg/m3 2 hours LD50 Inhalation Vapor Rat 78000 mg/m3 2 hours LD50 Intraperitoneal Rat Rat 78000 mg/kg LD50 Intraperitoneal Mouse 945 mg/kg LD50 Oral Rabit S 54 mg/kg LD50 Oral Rabit S 54 mg/kg LD50 Oral Rabit Rat 7800 mg/kg LD50 Oral Rabit 8700 mg/kg LD50 Oral Rabit 8700 mg/kg LD50 Oral Rabit 8700 mg/kg LD50 Oral Rat 787 mg/kg LD50 Oral Rat 784 mg/kg LD50 Subcutaneous Mouse 5954 mg/kg LD50 Subcutaneous Rat 6500 uL/kg LD50 Intraperitoneal Rabit 1 mL/kg LD50 Intraperitoneal Mouse 1230 mg/kg LD50 Intraperitoneal Mouse 1230 mg/kg LD50 Intraperitoneal Rabit 1540 mg/kg LD50 Intraperitoneal <					-
 LD50 Oral Mouse HD50 Oral Mouse LD50 Oral Mouse LD50 Oral LD50 Oral Rat LD50 Oral Rat LD50 Oral Rat LD50 Oral Rat C50 Inhalation Vapor Mouse Rat Mouse LD50 Oral Rat Rat C50 Inhalation Vapor Rat Rat Rat C50 Inhalation Vapor Rat <					-
 LD50 Oral Mouse LD50 Oral LD50 Oral Rat 2080 mg/kg LD50 Oral Rat 4600 mg/kg LC50 Inhalation Vapor Rat 4600 mg/kg LC50 Inhalation Vapor Rat Rabbit S g/kg LD50 Oral Rabbit S g/kg LD50 Intraperitoneal Guinea pig 1890 mg/kg LD50 Intraperitoneal Mouse 945 mg/kg LD50 Intraperitoneal Mouse 945 mg/kg LD50 Intraperitoneal Mouse 945 mg/kg LD50 Oral Rat 1380 mg/kg LD50 Oral Rat Rat 7872 mg/kg LD50 Oral Rabbit 8700 mg/kg LD50 Subcutaneous Guinea pig 5954 mg/kg LD50 Subcutaneous Rat 7872 mg/kg LD50 Subcutaneous Rat Rat 7800 mg/kg LD50 Intraperitoneal Rat Rat 7088 mg/kg LD50 Subcutaneous Rat 8000 ppm 4 hours LD50 Intraperitoneal Rabit 1 mL/kg LD50 Intraperitoneal Mouse 1230 mg/kg LD50 Intraperitoneal Mouse 1230 mg/kg LD50 Intraperitoneal Mouse 1230 mg/kg LD50 Intraperitoneal Rabit 1540 mg/kg LD50 Intraperitoneal Rabit 1540 mg/kg LD50 Intraperitoneal Rabit 1540 mg/kg LD50 Intraperitoneal Rat 1300 mg/kg LD50 Intraperitoneal Rat 13					-
LD50 OralRat2080 mg/kg-LD50 OralRat4600 mg/kg-LD50 Inhalation VaporRat78000 mg/kg-LC50 Inhalation VaporRat78000 mg/kg-LD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1980 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralMouse3625 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7872 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 IntraperitonealRat600 uL/kg-LD50 IntraperitonealRatbit1 mL/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperit			Mouse		-
LD50 OralRat4600 mg/kg-LC50 Inhalation VaporMouse18500 mg/m32 hoursLC50 Inhalation VaporRat78000 mg/m34 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRat11L/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-<		LD50 Oral	Mouse	2850 mg/kg	-
LD50 OralRat4600 mg/kg-LC50 Inhalation VaporMouse18500 mg/m32 hoursLC50 Inhalation VaporRat78000 mg/m34 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRat11L/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-<		LD50 Oral	Rat	2080 mg/kg	-
methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation VaporMouse18500 mg/m32 hoursLD50 Dermal LD50 Intraperitoneal LD50 IntraperitonealRabbit>5 g/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse945 mg/kg-LD50 Intraperitoneal LD50 OralGuinea pig5954 mg/kg-LD50 Oral LD50 OralGuinea pig5954 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7882 mg/kg-LD50 Dral LD50 SubcutaneousRat6500 uL/kg-LD50 Dral LD50 DralRat6500 uL/kg-LD50 Dral LD50 DralRat6500 uL/kg-LD50 Dral LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1540 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-<		LD50 Oral	Rat		-
 LC50 Inhalation Vapor Rat Rabbit Rat Rabbit Rat Rat<!--</td--><td>ethvl methacrvlate</td><td>LC50 Inhalation Vapor</td><td>Mouse</td><td></td><td>2 hours</td>	ethvl methacrvlate	LC50 Inhalation Vapor	Mouse		2 hours
LD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 OralRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 IntraperitonealRat1620 uL/kg- <td></td> <td></td> <td></td> <td></td> <td></td>					
LD50IntraperitonealGuinea pig1890 mg/kg-LD50IntraperitonealMouse945 mg/kg-LD50IntraperitonealRat1328 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralRabbit8700 mg/kg-LD50SubcutaneousGuinea pig5954 mg/kg-LD50SubcutaneousGuinea pig5954 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50SubcutaneousRat6000 µm4 hoursLD50LD50CralRat8000 µm4 hoursLD50LD50OralRat8000 µm4 hoursLD50LD50CralRat8000 µm4 hoursLD50IntraperitonealGuinea pig930 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1620 uL/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1620 uL/kg-LD50OralRat1620 uL/kg-LD50O		•			-
LD50 Intraperitoneal Mouse 945 mg/kg - LD50 Intraperitoneal Rat 1328 mg/kg - LD50 Oral Guinea pig 5954 mg/kg - LD50 Oral Rabbit 8700 mg/kg - LD50 Oral Rat 7872 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Mouse 5954 mg/kg - LD50 Subcutaneous Mouse 5954 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 6500 uL/kg - LD50 Subcutaneous Rat 8000 ppm 4 hours LD50 Intraperitoneal Guinea pig 930 mg/kg - LD50 Intraperitoneal Rabbit 1 mL/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Intraperitoneal Rat 1620 uL/kg - LD50 Inhalation Vapor Mouse 10 g/m³ 7 hours LC50 Inhalation Vapor Mouse 10 g/m³ 7 hours LC50 Inhalation Vapor Mouse 10000 mg/m³ 4 hours					
LD50 Intraperitoneal Rat 1328 mg/kg - LD50 Oral Guinea pig 5954 mg/kg - LD50 Oral Rabbit 8700 mg/kg - LD50 Oral Rat 7872 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 6500 uL/kg - LD50 Dermal Rat 8000 ppm 4 hours LD50 Intraperitoneal Guinea pig 930 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rabbit 1 mL/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Oral Rat 1620 uL/kg - LD50 Subcutaneous Rat 2170 mg/kg - LD50 Inhalation Vapor Mouse 10 g/m³ 7 hours LC50 Inhalation Vapor Mouse 10000 mg/m³ 4 hours					-
LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 OralRat6500 uL/kg-LD50 OralRat6000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1800 mg/m32 hoursLD50 Inhalation VaporMouse10 g/m37 hoursLC50 Inhalation VaporMouse		•			-
LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 OralRat6500 uL/kg-LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat10 g/m³7 hoursLD50 OralRat10 g/m³7 hoursLD50 OralRat10000 mg/m³2 hoursLD50 OralRat10000 mg/m³7 hoursLD50 SubcutaneousRat2170 mg/kg-LD50 OralRat1300 mg/m³7 hoursLD50 Inhal					-
LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat10 g/m³7 hoursLD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 OralRat1620 uL/kg- <td></td> <td></td> <td></td> <td></td> <td>-</td>					-
LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 OralRat6500 uL/kg-LD50 DermalRat8000 ppm4 hoursLD50 DermalRat8000 ppm4 hoursLD50 Inhalation Gas.Rat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 SubcutaneousRat1620 uL/kg-LD50 SubcutaneousRat1620 uL/kg-LD50 SubcutaneousRat16300 mg/m³7 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hours				3625 mg/kg	-
LD50 SubcutaneousGuinea pig Mouse5954 mg/kg-4-morpholinecarbaldehydeLD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat6500 uL/kg-LD50 OralRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1400 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLD50 DermalRat39000 mg/m³4 hoursLD50 DermalRat39000 mg/m³4 hours				8700 mg/kg	-
4-morpholinecarbaldehyde cyclohexanoneLD50 Subcutaneous LD50 OralMouse5954 mg/kg-4-morpholinecarbaldehyde cyclohexanoneLD50 Subcutaneous LD50 OralRat6500 uL/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hour					-
4-morpholinecarbaldehyde cyclohexanoneLD50 Subcutaneous LD50 Oral LC50 Inhalation Gas.Rat7088 mg/kg-LC50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 IntraperitonealRat8000 ppm4 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Mouse930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRabbit1540 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1800 mg/kg-LD50 Intraperitoneal LD50 OralRat1620 uL/kg-LD50 Oral LD50 OralRat1620 uL/kg-LD50 Subcutaneous LC50 Inhalation VaporRat2170 mg/kg-LC50 Inhalation Vapor LC50 Inhalation VaporMouse10000 mg/m³2 hoursLC50 Inhalation Vapor LC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation Vapor LC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation Vapor LC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation Vapor LC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhal					-
4-morpholinecarbaldehyde cyclohexanoneLD50 OralRat6500 uL/kg-LC50 Inhalation Gas. LD50 DermalRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³2 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation V			Mouse		-
cyclohexanoneLC50 Inhalation Gas. LD50 DermalRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LD50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLD50 DermalRat39000 mg/m³4 hours		LD50 Subcutaneous	Rat	7088 mg/kg	-
LD50 Dermal Rabbit 1 mL/kg - LD50 Intraperitoneal Guinea pig 930 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg - LD50 Oral Rat 1620 uL/kg - LD50 Oral Rat 1620 uL/kg - LD50 Subcutaneous Rat 2170 mg/kg - LD50 Subcutaneous Rat 2170 mg/kg - LD50 Inhalation Vapor Mouse 10 g/m ³ 7 hours LC50 Inhalation Vapor Mouse 10000 mg/m ³ 7 hours LC50 Inhalation Vapor Rat 39000 mg/m ³ 4 hours LD50 Dermal Rabbit 12300 uL/kg -	morpholinecarbaldehyde	LD50 Oral	Rat	6500 uL/kg	-
LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRat39000 mg/m³4 hours	/clohexanone	LC50 Inhalation Gas.	Rat	8000 ppm	4 hours
LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRat39000 mg/m³4 hours		LD50 Dermal	Rabbit	1 mL/kg	-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRat39000 mg/m³4 hours		LD50 Intraperitoneal	Guinea pig		-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					_
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 uL/kg-					_
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					_
LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat2170 mg/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-		•			
LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 OralRat2170 mg/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³4 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					-
LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 uL/kg-				1130 mg/kg	-
LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat39000 uL/kg-					-
LD50 OralRat1620 uL/kg-LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLC50 Inhalation VaporRat12300 uL/kg-					-
LD50 SubcutaneousRat2170 mg/kg-LC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					-
cumeneLC50 Inhalation VaporMouse15300 mg/m³2 hoursLC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					-
LC50 Inhalation VaporMouse10 g/m³7 hoursLC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					-
LC50 Inhalation VaporMouse10000 mg/m³7 hoursLC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-					
LC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-		•	Mouse		
LC50 Inhalation VaporRat39000 mg/m³4 hoursLD50 DermalRabbit12300 uL/kg-		LC50 Inhalation Vapor	Mouse		7 hours
LD50 Dermal Rabbit 12300 uL/kg -			Rat		4 hours
5					-
				•	-
afigura/Data of revision 110 2022				1	1
e of issue/Date of revision : 1-10-2022 Version : 1 e of previous issue : No previous validation 13/22 Akzo				. /	AkzoNob

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 BASE COAT MONO F15 MATT BASE MOUNICOT BLUE 22611

SECTION 11: Toxicological information

0			
LD50 Oral	Rat	2.9 g/kg	-
LD50 Oral	Rat	1400 mg/kg	-

Conclusion/Summary : Not available.

Product/ingredient name	Result	Species	Score	Exposure	Observation
n-butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
-	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Reaction mass of	Eyes - Mild irritant	Rabbit	-	87 mg	-
ethylbenzene and xylene		Dahbit		0.4 h a uma 5	
	Eyes - Severe irritant	Rabbit	-	24 hours 5	-
	Skin - Mild irritant	Rat	_	mg 8 hours 60 UI	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
	Skin - Moderate irritant	Rabbit	-	100 %	-
4-methylpentan-2-one	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
				UI	
	Eyes - Severe irritant	Rabbit	-	40 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 500	-
1 morpholipoporholdobydo	Even Mild irritent	Dabbit		mg 24 hours 500	
4-morpholinecarbaldehyde	Eyes - Mild irritant	Rabbit	-	mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 500	-
		T GOOR		mg	
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250	-
				ug	
	Eyes - Severe irritant	Rabbit	-	20 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
cumene	Eyes - Mild irritant	Rabbit	-	24 hours 500	-
	Even Mild imiterat	Dabbit		mg DC m r	
	Eyes - Mild irritant Skin - Mild irritant	Rabbit Rabbit	-	86 mg 24 hours 10	-
		Tabbit	-	mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 100	-
				mg	
Conclusion/Summary	: Not available.		I		
Sensitization					
Conclusion/Summary	: Not available.				
Mutagenicity					
Conclusion/Summary	: Not available.				
<u>Carcinogenicity</u>					
Conclusion/Summary	: Not available.				
Reproductive toxicity					
Conclusion/Summary	: Not available.				
-					
<u>Teratogenicity</u>					

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)



SECTION 11: Toxicological information

Product/ingredient name	Category	Route of exposure	Target organs
n-butyl acetate	Category 3	-	Narcotic effects
Reaction mass of ethylbenzene and xylene	Category 3	-	Respiratory tract irritation
4-methylpentan-2-one	Category 3	-	Narcotic effects
aromatic hydrocarbons, C9	Category 3	-	Respiratory tract irritation
	Category 3		Narcotic effects
Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, <2% aromatics	Category 3	-	Narcotic effects
methyl methacrylate	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene aromatic hydrocarbons, C9 Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, <2% aromatics Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

Information on the likely	: Not available.
routes of exposure	

Potential	acute	health	effects	

Eye contact	: Causes serious eye irritation.
Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.
Skin contact	: Causes skin irritation. May cause an allergic skin reaction.
Ingestion	: Can cause central nervous system (CNS) depression.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	Adverse symptoms may include the following: irritation redness
Ingestion	No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	15/22	AkzoNobel

SECTION 11: Toxicological information

Short term exposure		
Potential immediate effects	:	Not available.
Potential delayed effects	:	Not available.
Long term exposure		
Potential immediate effects	:	Not available.
Potential delayed effects	:	Not available.
Potential chronic health effe	ect	<u>S</u>
Not available.		
Conclusion/Summary	:	Not available.
General	:	May cause damage to organs through prolonged or repeated exposure. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	:	Suspected of causing cancer. Risk of cancer depends on duration and level of exposure.
Mutagenicity	:	No known significant effects or critical hazards.
Reproductive toxicity	:	No known significant effects or critical hazards.
Other information	:	Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

Product/ingredient name	Result	Species	Exposure
n-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours
Reaction mass of	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
ethylbenzene and xylene			
4-methylpentan-2-one	Acute LC50 505000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 540000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 537000 µg/l Fresh water	Fish - Pimephales promelas -	96 hours
		Juvenile (Fledgling, Hatchling, Weanling)	
	Chronic NOEC 78 mg/l Fresh water	Daphnia - Daphnia magna	21 days
	Chronic NOEC 168 mg/l Fresh water	Fish - Pimephales promelas - Embryo	33 days
methyl methacrylate	Acute LC50 191000 µg/l Fresh water	Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 159100 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 160200 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 150000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
	Acute LC50 130000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
cyclohexanone	Acute EC50 32.9 mg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth	72 hours
Date of issue/Date of revision	: 1-10-2022	Version :1	
Date of previous issue	: No previous validation	16/22 A	kzoNobel

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 BASE COAT MONO F15 MATT BASE MOUNICOT BLUE 22611

		phase	
	Acute LC50 630000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 527000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 732000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
cumene	Acute EC50 2600 µg/l Fresh water	Algae - Pseudokirchneriella subcapitata	72 hours
	Acute EC50 7.4 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours
	Acute EC50 7.5 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours
	Acute EC50 10.6 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours
	Acute EC50 10.6 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours
	Acute EC50 11.2 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours
	Acute LC50 7.4 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours
	Acute LC50 8 mg/l Marine water	Crustaceans - Artemia sp Nauplii	48 hours
	Acute LC50 20.3 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours
	Acute LC50 20.3 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	48 hours
	Acute LC50 6320 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 5100 µg/l Fresh water	Fish - Poecilia reticulata	96 hours
	Acute LC50 2700 µg/l Fresh water	Fish - Oncorhynchus mykiss	96 hours

Conclusion/Summary

: Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
n-butyl acetate	2.3	-	low
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
4-methylpentan-2-one	1.9	-	low
methyl methacrylate	1.38	-	low
4-morpholinecarbaldehyde	-	<1.9	low
2-methoxy-1-methylethyl acetate	1.2	-	low
cyclohexanone	0.86	-	low
cumene	3.55	35.48	low

12.4 Mobility in soil

Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

Date of issue/Date of revision	: 1-10-2022	Version :1	
Date of previous issue	: No previous validation	17/22	AkzoNobel

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	 Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Disposal considerations	 Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG		ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263	
14.2 UN proper shipping name	PAINT	PAINT	PAINT	
14.3 Transport hazard class(es)	3	3	3	
14.4 Packing group				
Date of issue/Date of re	vision : 1-10-2022	v	ersion :1	
Date of previous issue	: No previous	validation 18	8/22	AkzoNobe

SECTION 14: T	ranspo	ort	information		
14.5 Environmental hazards	No.			No.	No.
Additional informat	<u>ion</u>				
ADR/RID		:		ception This class 3 viscous liqu 50 L according to 2.2.3.1.5.1.	id is not subject to regulation in
IMDG		:		<u>ules</u> F-E, _S-E_ <u>ception</u> This class 3 viscous liqu 50 L according to 2.3.2.5.	id is not subject to regulation in
14.6 Special precaut user	tions for	:	-		ort in closed containers that are g the product know what to do in
14.7 Transport in bu according to IMO instruments	ording to IMO				
SECTION 15: F	Regulat	or	y information	1	
EU Regulation (EC)	No. 1907	/20	-	egislation specific for the subs	stance or mixture

Annex XIV				
None of the components a	re lis	ted.		
Substances of very high	con	<u>cern</u>		
None of the components a	re lis	ted.		
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.		
Other EU regulations				
VOC			2004/42/EC on VOC apply to this al data sheet for further informat	
VOC for Ready-for-Use Mixture	:	Not applicable.		
Industrial emissions (integrated pollution prevention and control) - Air	:	Listed		
Industrial emissions (integrated pollution prevention and control) - Water	:	Not listed		
Ozone depleting substanc Not listed.	<u>es (</u>	<u>1005/2009/EU)</u>		
Prior Informed Consent (P Not listed.	<u>IC) (</u>	<u>649/2012/EU)</u>		
Seveso Directive				
Date of issue/Date of revision		: 1-10-2022	Version :1	
Date of previous issue		: No previous validation	19/22	AkzoNobel

SECTION 15: Red	gulatory information
	ed under the Seveso Directive.
Danger criteria	
Category	
P5c	
Industrial use	: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.
NACE	: Not available.
UC62	: Not available.
International regulation	<u>ns</u>
<u>Chemical Weapon Cor</u>	vention List Schedules I, II & III Chemicals
Not listed.	
Montreal Protocol	
Not listed.	
Stockholm Conventior	n on Persistent Organic Pollutants
Not listed.	
Rotterdam Convention	n on Prior Informed Consent (PIC)
UNECE Aarhus Protoc Not listed.	ol on POPs and Heavy Metals
Inventory list	
Europe	: Not determined.
15.2 Chemical Safety Assessment	: No Chemical Safety Assessment has been carried out.
SECTION 16: Oth	ier information
Indicates information	that has changed from previously issued version.
Abbreviations and acronyms	 ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SCC = Segregation Crown

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

vPvB = Very Persistent and Very Bioaccumulative

SGG = Segregation Group



SECTION 16: Other information

Classification	Justification	
Flam. Liq. 3, H226	On basis of test data	
Skin Irrit. 2, H315	Calculation method	
Eye Irrit. 2, H319	Calculation method	
Skin Sens. 1, H317	Calculation method	
Carc. 2, H351	Calculation method	
STOT SE 3, H336	Calculation method	
STOT RE 2, H373	Calculation method	
Aquatic Chronic 3, H412	Calculation method	

Full text of abbreviated H statements

H225	Highly flommable liquid and vapor
	Highly flammable liquid and vapor.
H226	Flammable liquid and vapor.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H361f	Suspected of damaging fertility.
H373	May cause damage to organs through prolonged or repeated
	exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.

Full text of classifications [CLP/GHS]

Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 Aquatic Chronic 2 Aquatic Chronic 3 Asp. Tox. 1 Carc. 2 Eye Irrit. 2 Flam. Liq. 2 Flam. Liq. 3 Repr. 2 Skin Irrit. 2 Skin Sens. 1 Skin Sens. 1A STOT RE 2 STOT SE 3		ACUTE TOXICITY - Category 4 AQUATIC HAZARD (ACUTE) - Category 1 AQUATIC HAZARD (LONG-TERM) - Category 1 AQUATIC HAZARD (LONG-TERM) - Category 2 AQUATIC HAZARD (LONG-TERM) - Category 3 ASPIRATION HAZARD - Category 1 CARCINOGENICITY - Category 2 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2 FLAMMABLE LIQUIDS - Category 2 FLAMMABLE LIQUIDS - Category 3 TOXIC TO REPRODUCTION - Category 2 SKIN CORROSION/IRRITATION - Category 2 SKIN SENSITIZATION - Category 1 SKIN SENSITIZATION - Category 1 SKIN SENSITIZATION - Category 1A SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) -
		Category 3
Date of printing	: 1 October 2022	·
Date of issue/ Date of revision	: 1 October 2022	
Date of previous issue	: No previous validation	
Version	: 1	
Unique ID	:	

Notice to reader



SECTION 16: Other information

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

